久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Q and A with CEO

Takeda CEO: Patients to benefit from innovation drive

By Zhou Wenting in Shanghai | China Daily | Updated: 2019-08-09 10:27
Share
Share - WeChat
The logo of Japanese Takeda Pharmaceutical Co is seen at an office building in Glattbrugg near Zurich, in this March 7, 2012 file photo. [Photo/Agencies]

Japanese biopharmaceutical company Takeda Pharmaceutical Co Ltd completed the purchase of Shire Plc in January, making rare diseases another key business area in addition to oncology, gastroenterology, and neuroscience among others in the company's global business blueprint.

In an interview with China Daily when participating in a summer camp in Shanghai for children suffering from rare diseases from all over the country last month, Chief Executive Officer Christophe Weber said the company plans to make significant investments over the next five years in research and development in China, focusing on unmet medical needs in the country.

The combination of China's continued healthcare reforms and the government's focus on encouraging innovation, along with the company's robust plan to accelerate innovation in the country, will result in the availability of 10 of Takeda's innovative medicines in the coming years, including three for patients suffering from rare diseases.

What's Takeda's next-step development goal in the area of rare diseases?

Rare diseases are now a strategic area for Takeda. It's an area where we invest a lot in our R&D based on the innovative pipeline already in place. We intend to launch and introduce new medicines for patients in China. Some are already available in the Chinese market, and we are accelerating the launch of some others.

Currently, we are preparing five new drug applications in this area in China. Next year, we are expecting the approval of three such products.

For example, one drug that had been approved in the United States and Europe is to treat hereditary angioedema, a severe genetic disease creating immune reactions. So far there is no innovative therapy available for this disease, only palliative treatment.

We're also expecting drugs for patients suffering from Fabry (a rare disorder that arises from a deficiency of a particular enzyme) and Gaucher disease (a rare genetic disorder that results in serious bone damage and even death).There is no innovative therapy to treat Fabry in China, and for Gaucher, there is one drug introduced more than a decade ago.

The country's regulators have streamlined and accelerated new drug approvals for those with urgent clinical demand or treating rare diseases. How do you interpret such changes and how will they have an effect on the future performance of Takeda?

I'm impressed by the tremendous developments in China regarding the registration of new drugs, which has become much faster. The drug approval process today compared to even three years ago, is completely different. For an R&D-driven company like us, we now have the opportunity to bring our innovative portfolio to China.

In the next few years, we're planning to launch 10 new medicines across our portfolio in China, and the number is larger than the sum of new products launched in the past 15 years. And this shows that the measures introduced by the Chinese authorities for medical supervision have been transformative.

Another example is that Takeda launched an innovative medicine for the treatment of multiple myeloma, a type of blood cancer, last year. It was brought forward from the original estimated time frame of the 2019 financial year. Takeda received regulatory approval for the new drug in April 2018, and made the product available to patients three months later, almost a whole year in advance.

In the past year the drug has been used to treat a large number of patients in China.

How would you describe China's position in Takeda's global blueprint?

China is strategic and important, and it's a key priority for Takeda for various reasons. One is that now there is a clear policy that we've witnessed in which China aims to provide innovative medicines to patients, and our focus is innovative medicines, and therefore there is good convergence.

Also, the country's medical market is huge based on its vast population.

And Takeda is a global biopharmaceutical company that originated in Asia, and Japan and China are neighbors. Actually, Takeda began as a family business in 1781, originally focusing on traditional Chinese medicine.

Is there any detailed plan to boost investment in the Chinese market?

Across the pharmaceutical value chain in the past financial year, Takeda added more than $100 million to its investment in China, which has taken the company's registered capital in the country to nearly $200 million.

We have been increasingly investing in clinical development programs; for example, we want the development of all our new products in China to be synchronized with the progress in other regions in the world. This means China needs to be involved at an early stage in the development of new medicines.

The Takeda Development Center in Shanghai was established in 2012 to speed up the company's clinical trial efforts in China and focus on the development of innovative medicines for China and Asia. In 2017, it was upgraded as the company's R&D center for Asia. It's a strategic R&D center and it requires spending. All the products we are launching right now in the market come from this willingness to invest more.

When we develop a new medicine, we make sure that the development is suitable for four main markets - China, the US, Europe and Japan. It illustrates how strategic China is for us.

In March, Takeda invested a further 110 million yuan ($16 million) in the expansion of its Tianjin facility, which functions as the manufacturing final step for the Chinese market.

Takeda has its roots in Asia. Do you think it has an advantage in the Chinese market compared to other pharmaceutical companies, most of which are from Europe and the United States?

Our advantage may include a good relationship between China and Japan in various aspects, and geographical and cultural proximity. I think in talent development, we also have an advantage in recruiting Chinese people to work or go on exchange programs in Japan.

The Takeda Science Foundation actively strengthens Sino-Japanese medical exchanges and promotes cross-border medical cooperation and development. For the best part of the past four decades, the foundation has wholly funded more than 260 Chinese physicians to fulfill medical educational programs in Japan.

Another small advantage is that it's a short flight for me to come from Japan. I come to China every year, and I'm coming more often, especially when the environment is pro-innovation and the opportunity for growth is stronger than ever before.

The country has its Healthy China 2030 strategy and Shanghai has its goal of becoming a medical center in Asia. How do you think such initiatives will influence the development of pharmaceutical companies in the country?

Such strong ambitions to be at the forefront of innovation are beneficial for a market of rising openness and will attract more investment from businesses that focus on innovative medicine R&D.

I think it's an exciting time for the healthcare industry and for companies like Takeda at the moment because China is now, more than ever before, willing to embrace new medicines. It also provides more hope to fight against health issues for patients and doctors.

In the area of new medicine development, we are already working with and are exploring collaborations with a rising number of local partners, including established research institutions and hospitals. I do see that the research capability in China is really progressive. We are monitoring the innovative climate as we are really keen to partner with local universities and biotech startups.

Do you remember your first visit to China? How was it different from this visit?

My first visit to China was in the early 1990s when the streets were filled with bicycles, which have been largely replaced by automobiles today. I witnessed the huge economic development of China as well as the healthcare sector. It's understandable that after a country's economic development reaches a certain level, the government and society will invest more in healthcare.

I was a junior member of staff when I first visited China - a product manager looking for opportunities for market development. Over the years, I have had more opportunities to talk to local hospitals, research institutions and government officials, and feel that they have thrived on professionalism.

As a professional in the health industry for decades, what is your health advice for young people and children?

Enough physical exercise, healthy diet and good sleep are always the golden rules, and now we need to add a moderate use of digital products. That's the typical advice we should give to kids and the younger generation. Everybody should manage technology instead of being managed by technology.

Young workers should also strike a balance between work and life. It's easy these days to lose the balance as people may stay on call around the clock or be dragged into unhealthy lifestyles. Every one should be responsible for his or her lifestyle.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    毛毛毛毛毛毛毛片123| 亚洲人成色77777| 欧美日韩亚洲一二三| www.污污视频| 人人妻人人做人人爽| 五月天开心婷婷| 久久久精品在线视频| 300部国产真实乱| 婷婷六月天在线| 日本福利视频一区| 一区二区三区四区免费观看| 噼里啪啦国语在线观看免费版高清版| 久久亚洲国产成人精品无码区| 可以看污的网站| 十八禁视频网站在线观看| 国产成人一二三区| 亚洲网中文字幕| 中文字幕一区二区三区四区在线视频| 精品久久久久久无码中文野结衣| 在线视频观看91| 成人免费在线观看视频网站| 国产3p露脸普通话对白| 男女爱爱视频网站| 中文字幕在线观看日 | 婷婷激情综合五月天| 红桃av在线播放| 亚洲国产精品无码观看久久| 黑人巨茎大战欧美白妇 | 男的插女的下面视频| 四虎影院一区二区| 欧美特级aaa| 欧美伦理片在线看| 黄色国产精品视频| 丝袜老师办公室里做好紧好爽| 水蜜桃色314在线观看| 免费一级淫片aaa片毛片a级| 国产激情片在线观看| 亚洲小视频在线播放| 天堂网成人在线| 日韩视频在线观看一区二区三区| 亚洲欧美偷拍另类| www.精品在线| 欧美美女一级片| 美女在线视频一区二区| 中日韩av在线播放| 两性午夜免费视频| 国产四区在线观看| 国产婷婷一区二区三区| 少妇人妻大乳在线视频| 欧美精品久久久久久久自慰| 欧美在线一区视频| 精品这里只有精品| 日本精品一区二区三区四区| 欧美黄色免费影院| 波多野结衣作品集| 午夜两性免费视频| 久久久精品视频国产| 成人午夜免费剧场| 日本国产中文字幕| 九色在线视频观看| 91最新在线观看| 国产精品999.| 国产精品无码电影在线观看| 日韩伦理在线免费观看| 免费av网址在线| 国产又猛又黄的视频| 91亚洲一区二区| 免费的一级黄色片| 少妇性饥渴无码a区免费| 自拍偷拍 国产| 久久出品必属精品| 少妇大叫太大太粗太爽了a片小说| www插插插无码视频网站| 国产福利一区视频| 久久成年人网站| www精品久久| 日韩一级片播放| 中文字幕第22页| 黄色激情在线视频| 爆乳熟妇一区二区三区霸乳| 天天色天天综合网| 91动漫在线看| 十八禁视频网站在线观看| 成人手机视频在线| 日本www在线视频| 久久99999| 女人被男人躁得好爽免费视频| 97成人在线观看视频| 国产又粗又长又爽又黄的视频| 隔壁人妻偷人bd中字| 欧美婷婷精品激情| www.avtt| 色乱码一区二区三区在线| 国产日韩欧美大片| 激情婷婷综合网| 热久久最新地址| 国产精品拍拍拍| 国产尤物av一区二区三区| 人人干人人视频| 日本中文字幕在线视频观看| 亚洲国产精品三区| 精品一二三四五区| 污视频网址在线观看| av无码精品一区二区三区| 五月天综合婷婷| 久草在在线视频| 久久久久久久久久久综合| 亚洲视频第二页| 国产乱子伦农村叉叉叉| 日本一本在线视频| 好男人www社区| 欧美午夜小视频| 三年中国中文在线观看免费播放| 国产成人av影视| 日韩小视频网站| 天天综合成人网| 男人女人黄一级| 少妇av一区二区三区无码| 久久综合在线观看| 中文字幕在线观看第三页| 欧美成人三级在线视频| 欧美xxxx吸乳| 91高清国产视频| 国产三级日本三级在线播放| 成人一对一视频| 女人床在线观看| 国产欧美精品一二三| 91色国产在线| 久草精品在线播放| 亚洲精品无码国产| 色婷婷777777仙踪林| 亚洲欧美日韩精品一区| 九热视频在线观看| 激情内射人妻1区2区3区| av免费观看国产| 国产欧美日韩小视频| 日韩亚洲欧美一区二区| 在线观看日本www| aaa一级黄色片| 午夜免费看毛片| 四季av一区二区| 欧美黑人又粗又大又爽免费| 久在线观看视频| 欧美 日韩 国产 高清| 欧美日韩福利在线| 日韩精品在线中文字幕| 亚洲国产精品无码观看久久| 久久亚洲国产成人精品无码区| 欧美一级中文字幕| 久久久久久av无码免费网站下载| 无码人妻aⅴ一区二区三区日本| 久久精品国产99久久99久久久| 怡红院亚洲色图| 国产性生活一级片| 少妇熟女一区二区| 久久人妻无码一区二区| 国产一级黄色录像片| 玖玖精品在线视频| 亚洲中文字幕无码一区二区三区 | 国产91美女视频| 黄色一级片播放| 999香蕉视频| 天堂av在线网站| www.色欧美| 天天色天天干天天色| 亚洲黄色网址在线观看| 国内外成人激情免费视频| 视频一区二区视频| 9色视频在线观看| 色欲色香天天天综合网www| 无码精品a∨在线观看中文| 成人免费xxxxx在线视频| 在线观看国产一级片| 1314成人网| 精品少妇人欧美激情在线观看| 精品无码一区二区三区在线| av动漫在线观看| 91小视频网站| 男人j进女人j| 日本日本19xxxⅹhd乱影响| 人人爽人人av| 中文字幕55页| 欧美一级免费播放| www.xxx亚洲| 中文字幕12页| 久久av综合网| 成熟老妇女视频| 在线观看av免费观看| 妞干网在线播放| 午夜肉伦伦影院| www激情五月| 久久国产精品视频在线观看| 黄色免费网址大全| 最新av网址在线观看| 亚欧无线一线二线三线区别| 亚洲国产高清av| 国产精品自拍合集| 牛夜精品久久久久久久| avove在线观看| 十八禁视频网站在线观看|